Cephalosporin and fluoroquinolone combinations are highly associated with CTX-M β-lactamase-producing Escherichia coli: a case-control study in a French teaching hospital.

The aim of this study was to investigate the risk factors associated with CTX-M-producing Escherichia coli strains isolated from infected or colonized patients. From 191 clinical samples, a case-control study was designed. From January 2005 to December 2007, 98 hospitalized patients infected or colonized with CTX-M-producing E. coli were included in the study. They were matched 1 : 1 with controls that had a non-CTX-M-producing E. coli infection on the basis of the site of sample, the unit of hospitalization and the time at risk. The rate of CTX-M-producing E. coli among those producing extended spectrum β-lactamases was always ≥90% from 2005 to 2008. All strains were susceptible to carbapenems. However, we observed a high rate of co-resistance to ciprofloxacin (61%), sulphonamides (86%) and gentamicin (34%). Significant risk factors identified by multivariate analysis were recurrent infections (OR = 2.93), presence of artificial nutrition (OR = 3.99), and recent exposure to quinolones (OR = 4.39), third- or fourth-generation cephalosporin (OR = 3.49) and the combination of both antibiotic classes (OR = 5.50). This report highlights the dramatic increase of CTX-M-producing E. coli and the need for changes in the use of antimicrobial drugs and in infection control measures to manage this major health concern.

[1]  A. Oliver,et al.  Community-onset bacteremia due to extended-spectrum beta-lactamase-producing Escherichia coli: risk factors and prognosis. , 2010, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[2]  Y. Carmeli,et al.  A multinational survey of risk factors for infection with extended-spectrum beta-lactamase-producing enterobacteriaceae in nonhospitalized patients. , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[3]  K. Prasad,et al.  Extended spectrum beta-lactamases in Escherichia coli & Klebsiella pneumoniae & associated risk factors. , 2009, The Indian journal of medical research.

[4]  J. Blázquez,et al.  Effect of Subinhibitory Concentrations of Antibiotics on Intrachromosomal Homologous Recombination in Escherichia coli , 2009, Antimicrobial Agents and Chemotherapy.

[5]  F. Ariey,et al.  CTX-M β-Lactamases in Escherichia coli from Community-acquired Urinary Tract Infections, Cambodia , 2009, Emerging infectious diseases.

[6]  M. Mulvey,et al.  Mechanisms of resistance and mobility among multidrug-resistant CTX-M-producing Escherichia coli from Canadian intensive care units: the 1st report of QepA in North America. , 2009, Diagnostic microbiology and infectious disease.

[7]  F. Baquero,et al.  Increasing prevalence of ESBL-producing Enterobacteriaceae in Europe. , 2008, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

[8]  Kevin B Laupland,et al.  Antimicrobial susceptibility of well-characterised multiresistant CTX-M-producing Escherichia coli: failure of automated systems to detect resistance to piperacillin/tazobactam. , 2008, International journal of antimicrobial agents.

[9]  K. Laupland,et al.  Extended-spectrum β-lactamase-producing Enterobacteriaceae: an emerging public-health concern , 2008 .

[10]  P. J. Z. Teixeira,et al.  The effect of control group selection in the analysis of risk factors for extended spectrum beta-lactamase-producing Klebsiella pneumoniae infections. A prospective controlled study. , 2008, The Journal of hospital infection.

[11]  A. Apisarnthanarak,et al.  Clinical and molecular epidemiology of community-onset, extended-spectrum beta-lactamase-producing Escherichia coli infections in Thailand: a case-case-control study. , 2007, American journal of infection control.

[12]  I. Matic,et al.  Antibiotic‐mediated recombination: ciprofloxacin stimulates SOS‐independent recombination of divergent sequences in Escherichia coli , 2007, Molecular microbiology.

[13]  J. Lavigne,et al.  CTX-M β-Lactamase-Producing Escherichia coli in French Hospitals: Prevalence, Molecular Epidemiology, and Risk Factors , 2006, Journal of Clinical Microbiology.

[14]  M. Kaufmann,et al.  Epidemiology of infections caused by extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella spp.: a nested case-control study from a tertiary hospital in London. , 2006, The Journal of hospital infection.

[15]  Y. Chuang,et al.  Extended-spectrum beta-lactamases in Taiwan: epidemiology, detection, treatment and infection control. , 2006, Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi.

[16]  J. Ariza,et al.  Risk-factors for acquisition of extended-spectrum beta-lactamase-producing Escherichia coli among hospitalised patients. , 2006, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[17]  J. Rodríguez-Baño,et al.  Clinical and molecular epidemiology of extended-spectrum beta-lactamase-producing Escherichia coli as a cause of nosocomial infection or colonization: implications for control. , 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[18]  Robert A. Bonomo,et al.  Extended-Spectrum (cid:2) -Lactamases: a Clinical Update , 2005 .

[19]  D. Church,et al.  Community-Wide Outbreaks of Clonally Related CTX-M-14 β-Lactamase-Producing Escherichia coli Strains in the Calgary Health Region , 2005, Journal of Clinical Microbiology.

[20]  R. Colodner Extended-spectrum beta-lactamases: a challenge for clinical microbiologists and infection control specialists. , 2005, American journal of infection control.

[21]  G. Rossolini,et al.  Evolution of CTX-M-type beta-lactamases in isolates of Escherichia coli infecting hospital and community patients. , 2005, International journal of antimicrobial agents.

[22]  B. Schlemmer,et al.  Outbreak of nosocomial infections due toKlebsiella pneumoniae producing SHV-4 beta-lactamase , 1990, European Journal of Clinical Microbiology and Infectious Diseases.

[23]  J. Rodríguez-Baño,et al.  Epidemiology and Clinical Features of Infections Caused by Extended-Spectrum Beta-Lactamase-Producing Escherichia coli in Nonhospitalized Patients , 2004, Journal of Clinical Microbiology.

[24]  F. Pérez,et al.  Outbreak of SHV-5 beta-lactamase-producing Klebsiella pneumoniae in a neonatal-pediatric intensive care unit in Spain. , 2004, Microbial drug resistance.

[25]  R. Labia,et al.  First isolation of CTX-M15-producing Escherichia coli from two French patients. , 2003, The Journal of antimicrobial chemotherapy.

[26]  M. Lipsitch,et al.  Control-group selection importance in studies of antimicrobial resistance: examples applied to Pseudomonas aeruginosa, Enterococci, and Escherichia coli. , 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[27]  J. Patel,et al.  Extended-Spectrum β-Lactamase–Producing Escherichia coli and Klebsiella Species: Risk Factors for Colonization and Impact of Antimicrobial Formulary Interventions on Colonization Prevalence , 2002, Infection Control & Hospital Epidemiology.

[28]  D. Paterson Recommendation for treatment of severe infections caused by Enterobacteriaceae producing extended-spectrum beta-lactamases (ESBLs). , 2000, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[29]  L. Tzouvelekis,et al.  CTX-M-type β-lactamases: an emerging group of extended-spectrum enzymes , 2000 .

[30]  J. Ariza,et al.  Risk factors for faecal carriage of Klebsiella pneumoniae producing extended spectrum beta-lactamase (ESBL-KP) in the intensive care unit. , 1997, The Journal of hospital infection.

[31]  F. Goldstein,et al.  Communiqué 1992 du comité de l'antibiogramme de la société française de microbiologie , 1990 .

[32]  V. Jarlier,et al.  Extended broad-spectrum beta-lactamases conferring transferable resistance to newer beta-lactam agents in Enterobacteriaceae: hospital prevalence and susceptibility patterns. , 1988, Reviews of infectious diseases.